BC133 outperformed heterodimer BsAb. Female NSG mice were implanted IV with 1 million MOLM13 AML cells. Tumor growth was monitored by bioluminescence imaging (A) and expressed as total flux in p/s (B). ATCs (5 million-10 million/dose) were injected once weekly for 3 weeks starting 7 days after leukemia implantation. BC133 or the heterodimeric BsAb (0.1 μg) was injected 1 day before and 1 day after each T cell administration. To support T-cell persistence in vivo, 1000 IU IL-2 was administered subcutaneously 2 times per week.